Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Demographic and clinical features of the patient sample*

From: Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world

 

Northern Europe

N = 223

Western Europe

N = 198

Southern Europe

N = 480

Eastern Europe

N = 539

North America

N = 165

Latin America

N = 217

Africa & Middle East

N = 271

Southeast Asia

N = 48

Demographic and clinical features

 Female (NS)

170 (76.2)

150 (75.8)

377 (78.5)

393 (72.9)

138 (83.6)

152 (70.0)

194 (71.6)

33 (68.8)

 Age at onset, years (median [IQR])

3.5 [2.0, 7.9]

7.5 [3.0, 10.6]

3.5 [1.7, 7.0]

6.8 [3.0, 10.5]

7.3 [3.0, 10.6]

7.0 [4.0, 10.3]

6.8 [3.7, 9.8]

6.3 [2.6, 10.8]

 Age at onset

        

  ≤6 years of age

140 (62.8)

89 (44.9)

327 (68.1)

245 (45.5)

67 (40.6)

90 (41.5)

118 (43.5)

23 (47.9)

  6–12 years of age

18 (8.1)

36 (18.2)

29 (6.0)

101 (18.7)

28 (17.0)

28 (12.9)

25 (9.2)

7 (14.6)

  >12 years of age

65 (29.1)

73 (36.9)

124 (25.8)

193 (35.8)

70 (42.4)

99 (45.6)

128 (47.2)

18 (37.5)

 Age at visit, years

(median [IQR])

11.7 [8.2, 14.6]

12.5 [8.9, 15.6]

9.6 [5.8, 13.5]

12.8 [8.9, 15.7]

13.3 [10.7, 16.1]

13.3 [10.6, 15.2]

11.3 [8.0, 13.8]

11.3 [8.2, 14.1]

 Disease duration, years

(median [IQR])

5.4 [2.9, 8.5]

3.8 [1.6, 6.3]

4.2 [2.0, 7.2]

4.1 [1.9, 7.3]

4.4 [2.0, 8.8]

4.8 [2.4, 7.5]

3.2 [1.6, 6.0]

5.4 [2.9, 8.5]

 Interval onset-referral, years

(median [IQR])

0.2 [0.1, 0.7]

0.4 [0.2, 0.9]

0.3 [0.1, 0.8]

0.4 [0.1, 1.3]

0.3 [0.1, 0.8]

0.4 [0.2, 1.3]

0.5 [0.2, 1.6]

0.8 [0.4, 2.0]

 Uveitis ever

47 (21.1)

19 (9.6)

68 (14.2)

43 (8.0)

15 (9.1)

4 (1.8)

12 (4.4)

2 (4.2)

 Uveitis in patients with a disease duration > 4 years

36/146 (24.7)

14/92 (15.2)

45/254 (17.7)

25/278 (9.0)

13/89 (14.6)

3/123 (2.4)

5/107 (4.7)

2/27 (7.4)

 Active uveitis at visit (NS)

12 (5.4)

6 (3.0)

17 (3.7)

19 (3.5)

3 (1.8)

0 (0.0)

5 (1.8)

1 (2.1)

 ESR (median [IQR])

6.0 [3.0, 9.0]

8.0 [5.0, 14.0]

10.0 [5.0, 19.0]

12.0 [6.0, 21.0]

7.0 [4.0, 14.0]

16.0 [8.0, 27.0]

16.5 [8.8, 28.0]

21.0 [10.0, 31.2]

 Antinuclear antibodies

        

  Positive

88 (39.5)

101 (51.0)

301 (62.7)

184 (34.1)

59 (35.8)

82 (37.8)

66 (24.4)

16 (33.3)

  Negative

135 (60.5)

81 (40.9)

170 (35.4)

339 (62.9)

79 (47.9)

121 (55.8)

184 (67.9)

26 (54.2)

  Not available

0 (0.0)

16 (8.1)

9 (1.9)

16 (3.0)

27 (16.4)

14 (6.5)

21 (7.7)

6 (12.5)

 cDMARD ever

201 (90.1)

157 (79.3)

428 (89.2)

462 (85.7)

125 (75.8)

199 (91.7)

244 (90.0)

45 (93.8)

 bDMARD ever

118 (52.9)

74 (37.4)

206 (42.9)

198 (36.7)

88 (53.3)

76 (35.0)

90 (33.2)

4 (8.3)

  1. NS not significant, IQR interquartile range, ESR erythrocyte sedimentation rate, cDMARDs conventional disease modifying antirheumatic drugs, bDMARDs biological disease modifying antirheumatic drugs
  2. *Values are numbers (%) unless indicated otherwise. All the differences are statistically significant (p < 0.001), apart from gender difference (p = 0.19) and frequency of active uveitis (p = 0.39). See main text for post-hoc analysis
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096